A method for testing a prespecified subgroup in clinical trials
Top Cited Papers
- 1 February 2007
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 26 (19) , 3535-3549
- https://doi.org/10.1002/sim.2825
Abstract
In clinical trials, investigators are often interested in the effect of a given study treatment on a subgroup of patients with certain clinical or biological attributes in addition to its effect on the overall study population. Such a subgroup analysis would become even more important to the study sponsor if an efficacy claim can be made for the subgroup when the test for the overall study population fails at a prespecified alpha level. In practice, such a claim is often dependent on prespecification of the subgroup and certain implicit or explicit requirements placed on the study results due to ethical or regulatory concerns. By carefully considering these requirements, we propose a general statistical methodology for testing both the overall and subgroup hypotheses, which has optimal power and strongly controls the familywise Type I error rate. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 29 references indexed in Scilit:
- Subgroup Analyses in Randomized Clinical Trials: Statistical and Regulatory IssuesJournal of Biopharmaceutical Statistics, 2005
- On the efficiency of targeted clinical trialsStatistics in Medicine, 2005
- Surrogate Endpoints And FDA’s Accelerated Approval ProcessHealth Affairs, 2005
- Evaluating the Efficiency of Targeted Designs for Randomized Clinical TrialsClinical Cancer Research, 2004
- Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancerGynecologic Oncology, 2004
- Subgroup analyses in randomized trials: risks of subgroup-specific analyses;: power and sample size for the interaction testPublished by Elsevier ,2004
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancerCancer, 2003
- Vaccine Results Lose Significance Under ScrutinyScience, 2003
- Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problemsStatistics in Medicine, 2002
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987